Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status von Bazhenova, Lyudmila, Hodgson, J. Graeme, Langer, Corey J., Simon, George R., Gettinger, Scott N., Ou, Sai-Hong Ignatius, Reckamp, Karen L., West, Howard Jack, Chiappori, Alberto, Koh, Han A., Molina, Julian R., Shaw, Alice Tsang, Patel, Jyoti D., Favaro, Justin Peter, Haney, Jeff, Reichmann, William, Kerstein, David, Rivera, Victor M., Camidge, D. Ross

Volltext